Our goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002.
Robert Clarke - CEO Kinaset
Kinaset Therapeutics
Kinaset Therapeutics was founded in 2020 through a Series A round of 40 million USD by 5AM Ventures, Atlas venture and Gimv. Funds will be used to support the clinical development of KN-002, a novel dry powder inhalable pan-JAK inhibitor for the treatment of eosinophilic and non-eosinophilic severe asthma.
KN-002 comes with an exclusive global in-license and development agreement with Vectura Group plc (LSE:VEC) to develop and commercialize KN-002 (formerly known as VR588). A first clinical trial in healthy volunteers and patients are poised to begin in the first half of 2021.
Share
2020
3
US
When ambition meets ambition
Kinaset Therapeutics intends to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. Asthma is a complex and heterogeneous disease affecting over 300 million people worldwide, with approximately 10% of patients having severe asthma who suffer from frequent exacerbations, compromised lung function, and a reduced quality of life.
We are excited to be part of Kinaset Therapeutics, and to support the company in bringing KN-002 to the clinic. Kinaset Therapeutics perfectly fits Gimv’s strategy of investing in drug development companies combining solid science, a strong data package and an experienced team.
Together, we build a leading company
The best-in-class profile and tailormade dry-powder formulation captured our interest from the early start. Together with this very experienced and dedicated management team we are convinced KN-002 can make a real difference to severe asthma patients that have limited treatment options today.
